Long non-coding RNA 1308 promotes cell invasion by regulating the miR-124/ADAM 15 axis in non-small-cell lung cancer cells

Hongliang Li,1,* Xiaopeng Guo,1,* Qiuian Li,1,* Pengzhan Ran,1 Xudong Xiang,3 Yuncang Yuan,1 Tianqi Dong,1 Bei Zhu,1 Lei Wang,1 Fangfang Li,1 Chunyan Yang,1 Dengcai Mu,1 Dan Wang,4 Chunjie Xiao,1 Shangyong Zheng1

1School of Medicine, Yunnan University, Kunming, China; 2Department of Oncology, Kunming General Hospital of Chengdu Military Command, Teaching Hospital of Kunming Medical University, Kunming, China; 3Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China; 4Department of Pharmacy, Kunming General Hospital of Chengdu Military Command, Teaching Hospital of Kunming Medical University, Kunming, China

*These authors contributed equally to this work

Purpose: Emerging evidence suggests that many differentially expressed long non-coding RNAs (lncRNAs) are involved in tumorigenesis. However, the functional roles of these transcripts and the mechanisms responsible for their deregulation in non-small-cell lung cancer (NSCLC) remain elusive. Here, we identified a novel lncRNA (IncRNA 1308), which was significantly upregulated in NSCLC tissues and investigated its biological function and potential molecular mechanism.

Methods: Differences in the lncRNA expression profiles between NSCLC and tumor-adjacent normal tissues were assessed by IncRNA expression microarray analysis. The microRNA in vivo precipitation (miRIP) method was used to identify the targeting microRNAs (miRNAs) on IncRNA 1308, and luciferase reporter assays were performed. Loss-of-function studies were used to explore the effect of IncRNA 1308 on lung carcinogenesis in NSCLC cells.

Results: The novel IncRNA 1308 was upregulated in NSCLC tissues and cell lines. By using biotin-labeled IncRNA 1308 for miRIP in NSCLC cells and dual-luciferase reporter assays, the results suggested that miRNA-124 was associated with IncRNA 1308. Furthermore, the expression of a disintegrin and a metalloproteinase 15 (ADAM 15) was downregulated in NSCLC cells when silencing of IncRNA 1308, the target of oncogenic miR-124, inhibits NSCLC cell proliferation and invasion. Conversely, the expression of ADAM 15 was significantly increased, when inhibiting the expression of miR-124, and alleviated cell invasion inhibition.

Conclusion: The results suggested that IncRNA 1308 may function as a competing endogenous RNA (ceRNA) for miR-124 to regulate cell invasion through the miR-124/ADAM 15 signaling pathway, indicating that IncRNA 1308 plays an important role in the disease progression of NSCLC.

Keywords: lung cancer, lncRNA 1308, miR-124, ADAM 15, competing endogenous RNA

Introduction

Lung cancer is the most common leading cause of death worldwide. In China, more than 700,000 new cases of lung cancer are diagnosed, and approximately 60,000 patients die of lung cancer each year.1 In some regions, such as Xuanwei, Qujing, or Gejiu, in the Honghe autonomous prefecture of Yunnan Province, the incidence of lung cancer is one among the highest in China and in the world.2,3 Recently, a retrospective sampling survey reported mortality rates of lung cancer in Xuanwei of 98.10/105 in men and 83.21/105 in women.4 Approximately 85% of all lung cancer cases have been diagnosed as non-small-cell lung cancer (NSCLC), and tumor metastasis occurs in more than half of all patients.5 Despite several therapies used in the clinical treatment of NSCLC, such as radiation, chemotherapy, and surgical resection, the outcomes remain unsatisfactory, with a 5-year survival rate of only 17%.6 Therefore, exploring the
underlying mechanism of NSCLC and identifying potential therapeutic target become imperative requirements.

Long non-coding RNAs (lncRNAs) are a class of transcripts longer than 200 nt in size, which lack significant protein-coding capacity. Emerging data have suggested that lncRNAs are involved in a wide range of biological processes, such as cellular proliferation, apoptosis, and differentiation. In the past few years, substantial evidence indicates that some lncRNAs, such as MALAT1, MEG3, and TP73-AS1, could regulate cancer progression. Moreover, several lncRNAs have been reported to participate in NSCLC. For instance, overexpression of lncRNA HOXA11-AS could repress miR-200b and promote cell epithelial–mesenchymal transition in NSCLC, whereas upregulation of lncRNA 00673 promotes tumor proliferation through LSD1 interaction and repression of NCA LD in NSCLC.

Although only a small quantity of functional lncRNAs have been well studied nowadays, they have been shown to regulate gene expression at various levels, including chromatin modification, transcriptional regulation, and post-transcriptional regulation. Currently, the cross talk between lncRNAs and mRNAs as competing for shared microRNAs’ (miRNAs) response elements has been identified as a new regulatory mechanism. In other words, lncRNAs may function as competing endogenous RNAs (ceRNAs) to sponge miRNAs, thereby modulating the depression of miRNA targets and imposing an additional level of post-transcriptional regulation.

In a previous study, lncRNA HOTAIR has been reported to be a ceRNA that regulates HER2 expression by sponging miR-331-3p in gastric cancer. Peng et al reported that lncRNA MEG3, a ceRNA of miR-181s, could regulate gastric carcinogenesis and may serve as a potential target for antineoplastic therapies. Therefore, we hypothesize that some lncRNAs may also have functions like ceRNAs, which could link miRNAs and the post-transcriptional network in the disease development of NSCLC. However, the underlying mechanisms of lncRNAs involved in the disease progression of NSCLC remain to be elucidated and characterized. Also, previous studies of occurrences of NSCL in Xuanwei (Xuanwei lung cancer [XWLC]) are focused mainly on its epidemiology, and little is known about the underlying mechanisms.

In this study, differences in the lncRNA expression profiles between NSCLC and tumor-adjacent normal tissues were assessed by lncRNA expression microarray analysis. We first identified that lncRNA 1308, a novel lncRNA, was overexpressed in NSCLC tissues compared with adjacent normal tissues. Then, we studied the underlying mechanisms involved in this phenomenon and found that knockdown of lncRNA 1308 decreased the expression of a disintegrin and a metallo-proteinase 15 (ADAM 15) by negatively regulating miR-124. Overexpression of ADAM 15 has been observed in several types of cancers and is involved in the progression of metastatic tumor, and previous literature also demonstrated that ADAM 15 can upregulate the expression of matrix metalloproteinase 9 (MM9, a key regulator of cancer invasion and metastasis), thus promoting lung cancer cell invasion. Taken together, this study provides the first evidence for a positive lncRNA 1308/ADAM 15 correlation and cross talk between miR-124, lncRNA 1308, and ADAM 15, shedding new light on NSCLC treatment.

**Materials and methods**

**Specimens and cell lines**

This research was in accordance with the requirements of the Declaration of Helsinki. Forty lung cancer tissues and the corresponding non-tumor tissues were obtained in accordance with the protocol approved by the ethics committee of the Third Affiliated Hospital of Kunming Medical University, Kunming, China. The patients received the necessary information concerning the study, and the written informed consent was obtained from all included individuals. The human lung cancer cell lines A549, H1975, and H1299, and the human lung normal cell line BESA-2B, were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in the supplemented media according to the ATCC’s recommendation. XWLC and Gejiu lung cancer (GLC), the local cell lines, were isolated from the cancer tissues of the patients who lived in Yunnan Province and were cultured in regular DMEM containing 10% FBS (vol/vol) as HEK-293T cells (ATCC). Cells were cultured at 37°C in a humidified atmosphere containing 5% CO₂.

**RNA isolation and quantitative reverse transcription PCR (qRT-PCR) analysis**

Total RNA was extracted from lung cancer tissues, adjacent non-tumor tissues, and lung cancer cell lines by using TRIzol according to the manufacturer’s instructions. qRT-PCR assay was performed using SYBRgreen PCR Master Mix in a Fast Real-time PCR 7500 System (Thermo Fisher Scientific, Waltham, MA, USA). The sequences of gene-specific primers are listed in Table S1. β-Actin was used as an internal control for normalization and quantification of lncRNA 1308 expression. The relative expression level was calculated using the 2−ΔΔCt method.

**Human lncRNA microarray assay**

Total RNA from 15 pairs of NSCLC and adjacent noncancerous lung tissues was isolated using the TRIzol agent...
mimics was 5′-AGA ATT -3′

ACG UTT -3′

-UUC UCC GAA CGU GUC

′

′

′

′

trol siRNA were as follows: 5′-GAC CUC UCC GTT -3′ (antisense). The sequences of con-

-lncRNA 1308 siRNA were as follows: 5′-UUC ACC UCU

′ (sense) and 5′-lncRNA 1308 mRNA was amplified by the

sequence of human miR-124 inhibitors was 5′-CAG UAC UUU

UGU GUA GUA CAA-3′. The transfections were performed with

INTERFERin reagent (Polyplus-transfection). The final

concentration of miRNA mimics was 50 nmol/L, the final

concentration of miRNA inhibitors was 100 nmol/L, and the

final concentration of siRNAs was 20 nmol/L.

To generate pGL3-lncRNA 1308 constructs, the

sequence of lncRNA 1308 mRNA was amplified by the

primers listed in Table S1. The fragments were inserted into

pGL3 with the designed cutting sites KpnI and XhoI. The

transfections were performed with INTERFERin reagent

(Polyplus-transfection). The final concentration of plasmids

was 100 ng.

**microRNA in vivo precipitation (miRIP) assay**

All the following experiments were performed as previously
described. The probes that were used are listed in Table S2. Cells

were transfected by the biotin-tagged specific probe or control

probe and harvested 24 hours after transfection. Cells were cross-linked by formaldehyde, equilibrated in
glycine buffer, and scraped with lysis buffer. Cell samples

were sonicated and then centrifuged. The supernatant was

transferred to a 2 mL tube and 50 µL was separately saved for

analysis. The supernatant lysate was incubated with M-280

beads for 1 hour while rotating. The beads–sample mixture

was washed and incubated to reverse the formaldehyde cross-

links. Subsequently, RNAs were repurified by TRIzol. A

duplex microRNA array was used to analyze the sequences of

184 miRNAs simultaneously from a single RT-PCR reaction
to discover the associated miRNAs that would target lncRNA

1308 in XWLC cells (the primers used for multiplex miRNA

arrays are provided in Table S3).

**Oligonucleotide and plasmid transfection**

RNA oligos were chemically synthesized and purified by GenePharma Co., Ltd. (Shanghai, China). The sequences of

lncRNA 1308 siRNA were as follows: 5′-CGG AGA GGU

CAG AGG UAG ATT-3′ (sense) and 5′-UCU ACC UCU

GAC CUC UCC GTT-3′ (antisense). The sequences of con-

trol siRNA were as follows: 5′-UUCC GAA CGU GUC

ACG UTT-3′ (sense) and 5′-ACG UGA CAC GUU CGU

AGA ATT-3′ (antisense). The sequence of human miR-124

mimics was 5′-UAA GGC ACG CGG UGA AUG CC-3′. The

sequence of negative control oligonucleotides for miRNA

was 5′-CAC UAC UUU GUGA GAU AAG CC-3′. The

sequence of human miR-124 inhibitors was 5′- GGC AUU

CAC CGC GUG CCU UA-3′. The sequence of negative

control oligonucleotides for miRNA was 5′-CAG UAC UUU

UGU GUA GUA CAA-3′. The transfections were performed with

INTERFERin reagent (Polyplus-transfection). The final

concentration of miRNA mimics was 50 nmol/L, the final

concentration of miRNA inhibitors was 100 nmol/L, and the

final concentration of siRNAs was 20 nmol/L.

In vitro invasion assays

The 24-well transwell chambers coated with Matrigel (BD Biosciences, San Jose, CA, USA) were used to determine
the invasive ability of lung cancer cells. Transfected cells in

serum-free medium were seeded at the concentration of 5×10^4
in the top chamber, and the RPMI-1640 containing 10% FBS

with INTERFERin reagent (Polyplus-transfection). The final

concentration of plasmids was 100 ng.

Cells that migrated to the underside of the membrane were fixed with 4% paraformaldehyde (Sigma-Aldrich Co., St Louis, MO, USA), stained with crystal violet (Beyotime, Shanghai, China), imaged, and counted using a

microscope (Leica Microsystems, Wetzlar, Germany) after

24 hours. All experiments were performed in triplicate.
Gel electrophoresis and immunoblotting
Cells were lysed in RIPA lysis buffer (Beyotime) containing 1% protease inhibitor Cocktail (Sigma-Aldrich Co.). Protein extract (20 µg) from the cell lysis was separated in a 4%–20% Tris-glycine gel and then transferred to a polyvinylidene fluoride (PVDF) membrane (Immobilon-P transfer membranes; EMD Millipore, Billerica, MA, USA). After blocking with 5% non-fat dry milk in PBS with 0.1% Tween-20 for 2 hours at room temperature, the blots were probed with 1:200 dilution of primary antibody against ADAM 15 (ab12698; Abcam, Cambridge, UK) and β-actin (c-11; Santa Cruz Biotechnology Inc., Dallas, TX, USA) overnight at 4°C. The blots were then probed with a 1:750 dilution of secondary antibodies for 1 hour at room temperature, followed by washing in PBS with 0.1% Tween-20 and detected using an Odyssey Scanning system.

Statistical analyses
SPSS 16.0 statistical software was used to perform statistical analyses. Data are shown as mean ± SD. Student’s t-test or non-parametric Mann–Whitney U test was used to analyze the differences between the 2 groups, and multiple comparisons were assessed by 1-way ANOVA followed by Dunnett’s test. Statistical significance was defined as the P-value less than 0.05.

Results
The novel IncRNA 1308 is upregulated in NSCLC tissues and cell lines
We performed a human IncRNA expression microarray on 15 pairs of NSCLC and adjacent non-cancerous lung tissues. Since the threshold had been set for upregulated and downregulated genes at a fold change of ≥2.0 and a P-value of <0.05, a total of 913 upregulated and 2,253 downregulated IncRNAs were identified in NSCLC samples compared with adjacent normal lung tissues, as depicted in the heat map (Figure 1). The top 10 upregulated IncRNAs in NSCLC tissues are listed in Table 1. We selected IncRNA 1308 for the subsequent analysis. For further validation, the expression levels of IncRNA 1308 were also investigated by using qRT-PCR assay in 40 pairs of lung cancerous, paracancerous tissues, and 5 cell lines. As shown in Figure 2A, the expression level of IncRNA 1308 was significantly increased in NSCLC tissues compared with that in adjacent normal tumor tissues. In addition, the expression of IncRNA 1308 was also upregulated in NSCLC cell lines, including A549, H1299, H1975, XWLC, and GLC, compared with that in the human lung normal cell line BESA-2B (Figure 2B).
lncRNA1308 promotes cell invasion in NSCLC cells

Table 1 Top 10 upregulated lncRNAs in NSCLC tissues

| Probe name | Gene symbol                | P-value     | FC    | Regulation |
|------------|----------------------------|-------------|-------|------------|
| C_15547    | IncRNA NONHSAG038390       | 2.03E-06    | 28.39 | Up         |
| C_79834    | IncRNA 1308                | 7.35E-09    | 23.60 | Up         |
| C_1346     | IncRNA SLC32A1             | 8.15E-05    | 11.10 | Up         |
| C_64647    | IncRNA ELTD1-2             | 2.55E-05    | 8.69  | Up         |
| C_16443    | IncRNA PVT1-10B            | 2.10E-08    | 6.37  | Up         |
| C_44036    | IncRNA PIK3C2G-2           | 1.59E-06    | 5.90  | Up         |
| C_87304    | IncRNA NONHSAG047350       | 3.60E-06    | 5.68  | Up         |
| C_2609     | IncRNA TSSK2-2             | 1.92E-05    | 5.62  | Up         |
| C_89598    | IncRNA OR4Q3-3             | 0.001056    | 5.05  | Up         |
| C_33744    | IncRNA EFR3A-5             | 1.12E-07    | 4.98  | Up         |

Abbreviations: FC, fold change; lncRNA, long non-coding RNA; NSCLC, non-small-cell lung cancer.

Downregulation of lncRNA1308 inhibits cell invasion in NSCLC cells

Loss-of-function studies were performed to investigate the effect of lncRNA1308 on lung carcinogenesis in NSCLC cells, XWLC and GLC cell lines, which were isolated from the NSCLC tissues of the patients from Xuanwei and Gejiu, respectively. lncRNA1308 siRNA and negative control oligonucleotides were transiently transfected into 2 specific lung cancer cell lines: XWLC and GLC cell lines. Results from qRT-PCR revealed a significant decrease in the expression level of lncRNA1308 (Figure 3A). Furthermore, the functional role of lncRNA1308 in the invasion of NSCLC cells was also investigated by performing invasion assays. Silencing of lncRNA1308 in XWLC and GLC cells resulted in significant suppression of cell invasion capacity (Figure 3B). These data suggest that lncRNA1308 modulated NSCLC cell viability and that the downregulation of lncRNA1308 inhibited NSCLC cell invasion capacity.

IncRNA1308 directly interacts with miR-124

lncRNAs could serve as ceRNAs to sponge miRNAs, thereby regulating gene expression. To understand the mechanism by which lncRNA1308 suppresses lung cancer cell invasion capacity, the miRIP method was used to identify the targeting miRNAs on lncRNA1308. Ten probes of lncRNA1308 were transfected into XWLC cells to hybridize with lncRNA1308 mRNA for 24 hours (Figure 4A). The associated miRNAs of lncRNA1308 were purified using Streptavidin Dynabeads (M-280) and isolated by TRIzol. RT-PCR detection of mRNA extracted from the transfected XWLC cells demonstrated a specific enrichment for the miRNAs of lncRNA1308 (Figure 4B). Moreover, a multiplex miRNA
array was used to analyze the sequences of 184 miRNAs simultaneously from a single RT-PCR reaction to discover the associated miRNAs that would target IncRNA 1308 in XWLC cells. miR-124, which interacted with IncRNA 1308 mRNA most robustly, was selected for the next immediate research (Figure 4C; Table 2).

**IncRNA 1308 is a target of miR-124 and controls the miR-124 target ADAM 15**

According to the data from DIANA-TarBase v8.0 (http://carolina.imis.athena-innovation.gr/diana_tools/web/index.php?r=tarbase8%2Findex), miR-124 was found to target ADAM 15, which was associated with multiple cellular functions including metastatic progression.22 Therefore, we assumed that IncRNA 1308 could act as a ceRNA for ADAM 15 in NSCLC cells. To validate our hypothesis, first, luciferase reporter assays were performed in HEK 293 T cells. We cloned IncRNA 1308 and ADAM 15 3’-UTR sequence, as indicated in Figure 5A and B, into the luciferase reporter plasmid. Second, these recombinant luciferase reporter plasmids were cotransfected with miR-124 mimics or negative control oligonucleotides into HEK 293 T cells for 36 hours, and the luciferase activity was measured in these transfected cells. As shown in Figure 5C and D, miR-124 transfection caused a significant decrease in luciferase activity in cells transfected with the reporter plasmid with IncRNA 1308 and ADAM 15 3’-UTR sequence, but no change in the cells transfected with reporter plasmids without the targeting sequence. Third, we explored whether endogenous ADAM 15 in lung cancer cells was regulated by a similar mode. XWLC and GLC cells were transfected with miR-124 mimics or negative control oligonucleotides. The results of Western blotting showed that the ADAM 15 protein level was consistently and substantially downregulated

---

**Figure 3** Downregulation of IncRNA 1308 suppresses cell invasion in lung cancer cells.

**Notes:** (A) IncRNA 1308 expression was quantified by qRT-PCR analysis. IncRNA 1308 expression was interfered in both XWLC and GLC cells. (B) The invasive ability of XWLC and GLC cells was evaluated by in vitro invasion assays after transfection of NC and siRNA of IncRNA 1308. Results are presented as mean ± SD. **P<0.01.** Magnification 100×.

**Abbreviations:** GLC, Gejiu lung cancer; IncRNA 1308, long non-coding RNA 1308; qRT-PCR, quantitative reverse transcription PCR; NC, negative control oligonucleotides; XWLC, Xuanwei lung cancer.
**IncRNA1308 promotes cell invasion in NSCLC cell lines**

**Discussion**

Recently, the roles of lncRNAs have attracted much attention, especially carcinogenesis and cancer progression.\(^{23}\) As their expression and function in NSCLC development remain unclear, we screened the differentially expressed lncRNAs among NSCLCs, matched non-tumor lung tissues through chip microarray, and focused on the roles and underlying mechanisms of aberrant lncRNAs expression in NSCLC progression. We first identified IncRNA 1308, which was overexpressed in NSCLC tissue samples. Consistently, the

by miR-124 (Figure 5E). These results suggest that both IncRNA 1308 and ADAM 15 are directly targeted by the shared microRNA, which is miR-124.

**IncRNA 1308 acted as a ceRNA for ADAM 15 to inhibit cell invasion in lung cancer cells**

We found that IncRNA 1308 could promote cell invasion of lung cancer cells and both IncRNA 1308 and ADAM 15 are directly targeted by the shared miR-124. Therefore, we hypothesized that IncRNA 1308 could regulate cell invasion in NSCLC cells by acting as a ceRNA for ADAM 15. As expected, the interference of IncRNA 1308 in XWLC and GLC cells decreased the accumulation of ADAM 15, whereas inhibiting miR-124 expression in XWLC and GLC cells markedly increased the expression of ADAM 15 (Figure 6A). In line with these results, knockdown of IncRNA 1308 significantly inhibited cell invasion in XWLC and GLC cells, while it inhibited miR-124 expression in XWLC and GLC cells, which markedly alleviated the inhibition of IncRNA1308-induced cell invasion (Figure 6B). Taken together, these results demonstrate that IncRNA 1308 could regulate lung cancer cell invasion through acting as a ceRNA for ADAM 15.

**Table 2 Relative miRIP isolation of miRNAs in XWLC cells using IncRNA 1308 probes (IncRNA1308/control >10)**

| miRNA   | IncRNA 1308/control |
|---------|---------------------|
| miR-124 | 170.1               |
| miR-134 | 61.4                |
| miR-191 | 40.8                |
| miR-106a| 28.4                |
| miR-107 | 22.3                |
| miR-22  | 15.5                |
| miR-23a | 15.2                |
| miR-302b| 13.8                |
| miR-182 | 13.0                |
| miR-27b | 12.6                |
| let-7b  | 11.9                |
| miR-296 | 10.9                |
| miR-16  | 10.1                |

Abbreviations: lncRNA, long non-coding RNA; miRIP, microRNA in vivo precipitation; miRNA, microRNA.
expression level of lncRNA 1308 was obviously higher in NSCLC cell lines compared to that of the normal cell lines. Mechanistic analysis revealed that knockdown of lncRNA 1308 inhibits NSCLC cell invasion, and lncRNA 1308 affects the interaction between miR-124 and ADAM 15 3′-UTR to regulate the expression of ADAM 15 by functioning as a ceRNA, thereby contributing to NSCLC progression. These results indicate that lncRNA 1308 plays a vital role in the modulation of oncogenic properties and the disease progression of NSCLC in a direct manner; these may be new research directions and become potential therapeutic options that consider lncRNA 1308 as a novel prognostic marker and therapeutic target in NSCLC.

Although thousands of lncRNAs have recently been identified, the functional characterization of lncRNAs has just begun. Currently, lncRNAs have been reported to regulate various cellular functions through different molecular mechanisms such as chromatin modification, transcriptional regulation, and post-transcriptional regulation. \(^8,24\) Recently, lncRNAs have been shown to serve as ceRNAs to sponge miRNAs, consequently modulating the derepression of miRNA targets.\(^{14,23}\) For example, Liu et al\(^{25}\) found that lncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells by upregulating EZH2. lncRNA BC032469 has been identified as a tumor-related molecule in gastric cancer by interfering miR-1207-5p.\(^{26}\) Together with miRNAs and their target gene, lncRNA–miRNA–mRNA axis may be an extensive regulatory network in gene expression, and their dysregulation may lead to disease progression including the development of cancer. This presumption may lead to interesting future studies that elucidate the regulatory network of non-coding...
lncRNAs and coding genes in cancer biology. Currently, candidate lncRNAs, and miRNAs targeted by lncRNAs, are mostly predicted and selected by literature, which seems to lack foresight. Precisely, determining the candidate lncRNAs that are involved in NSCLC progression, and which specific miRNA binds to a certain lncRNA, is important for investigating the mechanisms of lncRNA functions. Recently, Su et al. reported a new method, called miRIP, to identify which type of miRNAs can bind to the specific mRNA in a cell. By using the miRIP approach, the potential interaction between miR-92a and p21, and between miR-197 and STAT3, was elucidated in recent studies. In this study, by completing lncRNA expression microarray analysis, followed by performing RIP using a lncRNA 1308-specific probe, we found that miR-124 was the lncRNA 1308-binding miRNA, and we then proved that lncRNA 1308 functioned as the sponge of the miR-124. Thus, the miRIP approach would be a practical and useful method to identify the true and definite interaction between miRNAs and lncRNAs, especially considering that the lncRNA–miRNA interaction network is relatively complicated. Previous studies have shown that miR-124 is deregulated in several cancers. Sun et al. found that downregulation of miR-124 was significantly associated with poor prognosis in patients with pancreatic cancer.

Figure 6 lncRNA 1308 acts as a ceRNA to regulate ADAM 15 levels and suppresses cell invasion in lung cancer cells. Notes: (A) lncRNA 1308 acts as a ceRNA to inhibit ADAM 15 expression in lung cancer cells. XWLC and GLC cells were transfected with lncRNA 1308 siRNA and/or infected with miR-124 inhibitors, and the expression of ADAM 15 was analyzed by Western blotting. (B) lncRNA 1308 acts as a ceRNA to inhibit cell invasion. XWLC and GLC cells were transfected with lncRNA 1308 siRNA and/or infected with miR-124 inhibitors, and the invasive ability of cells was evaluated by in vitro invasion assays. Results are presented as mean ± SD. **P < 0.01. Anti-124, miR-124 inhibitor. Magnification 100×.

Abbreviations: ADAM15, a disintegrin and a metalloproteinase 15; ceRNA, competing endogenous RNA; GLC, Gejiu lung cancer; IncRNA 1308, long non-coding RNA 1308; XWLC, Xuanwei lung cancer.
ductal adenocarcinoma. Interestingly, the recent evidence further showed that miR-124 can suppress NSCLC cell migration and invasion activity by targeting zinc finger e-box binding homeobox 1 (ZEB1).19 Thus, these results suggest that miR-124 may function as an important regulatory gene in the development of NSCLC.

By using bioinformatics analysis, ADAM 15 was predicted to be a downstream target of miR-124. In this study, a luciferase reporter assay and rescue experiment confirmed that miR-124 targets 3¢-UTR of ADAM 15 to suppress the expression of ADAM 15 and inhibit NSCLC invasion. ADAM 15 is a membrane-associated proteinase belonging to the ADAM family.19 The ADAMs are members of the metzincin superfamily of matrix metalloproteinases. To date, 21 functional ADAMs have been described in humans and 40 have been described in different organisms.18 Recently, specific ADAMs have been described in different organisms.18 Specifically, ADAMs have been implicated in many diseases, including rheumatoid arthritis, atherosclerosis, and cancer.18,30,31 As a catalytic active member of the ADAM family, ADAM 15 is the only ADAM containing an arginine–glycine–aspartic acid (RGD) motif in the disintegrin domain. The RGD motif of ADAM 15 interacts with integrins α5β1 and α6β1 to regulate cell adhesion and motility.19,31 ADAM 15 is widely expressed in normal tissues and cancer cell lines. Overexpression of ADAM 15 has been reported in many solid tumors including those of breast, lung, colorectal, ovarian, and prostate cancers.17,19,32,33 It is believed that the tumor-promoting action of ADAM 15 results from disruption of cell–cell and cell–matrix adhesion and from release of membrane-bound growth factors.28,34,35 Accordingly, ADAM 15 deregulation has been linked to poor patient outcome in lung and colon cancers.19,32 Thus, there is accumulating evidence that ADAM 15 may play a key role in cancer biology. Furthermore, functional studies have indicated that ADAM 15 could support prostate cancer metastasis by modulating tumor cell–endothelial cell interaction in PC-3 prostate cancer cells,22 and Dong et al.19 demonstrated that ADAM 15 directly activates MMP9 to promote cell migration and invasion in lung cancer cells. Consistently, our results showed that interference of lncRNA 1308 in XWLC and GLC cells decreased the accumulation of ADAM 15 and inhibited cell invasion, whereas inhibited miR-124 expression in XWLC and GLC cells markedly increased the expression of ADAM 15 and alleviated cell invasion inhibition. Therefore, our data not only supported a pro-metastatic role of ADAM 15 in NSCLC progression but also revealed a novel mechanism of lncRNA in promoting cancer cell invasion through indirectly targeting ADAM 15 activation.

Conclusion
We first identified that IncRNA 1308, a novel IncRNA that was significantly overexpressed in NSCLC tissues and cells, competitively binds to miR-124 and subsequently upregulated the expression of its target gene ADAM 15 to promote the invasion of NSCLC cells. This IncRNA 1308/miR-124/ADAM 15 regulatory network may shed light on tumorigenesis in NSCLCs, and it may be valuable for the development of novel diagnostic and treatment approaches for NSCLC.

Acknowledgments
This work was financially supported by the National Natural Science Foundation of China (Nos. 81860494, 81860499, 81460435, and 81860638), the Yunnan Applied Basic Research project (No. 2017FB138), and the Science Research Foundation of the Yunnan Province Education Department (No. 2016ZZX014).

Author contributions
HL Li, CJ Xiao, and SY Zheng conceived and designed the experiments; HL Li, XP Guo, QT Li, and PZ Ran performed the experiments; XD Xiang, YC Yuan, TQ Dong, and B Zhu analyzed the data; L Wang, FF Li, CY Yang, DC Mu, and D Wang contributed reagents/materials/analysis tools; HL Li and SY Zheng wrote the paper. All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References
1. She J, Yang P, Hong Q, Bai C. Lung cancer in China: challenges and interventions. Chest. 2013;143(4):1117–1126.
2. Barone-Adesi F, Chapman RS, Silverman DT, et al. Risk of lung cancer associated with domestic use of coal in Xuanwei, China: retrospective cohort study. BMJ. 2012;345:e5414.
3. Zhang Y, Xue Q, Pan G, et al. Integrated Analysis of Genome-Wide Copy Number Alterations and Gene Expression Profiling of Lung Cancer in Xuanwei, China. PLoS One. 2017;12(1):e0169098.
4. Wu H, Meng S, Xu Q, et al. Gene expression profiling of lung adenocarcinoma in Xuanwei, China. Eur J Cancer Prev. 2016;25(6):508–517.
5. Chen JH, Zhou LY, Xu S, Zheng YL, Wan YF, Hu CP. Overexpression of lncRNA HOXA11-AS promotes cell epithelial-mesenchymal transition by repressing miR-200b in non-small cell lung cancer. Cancer Cell Int. 2017;17:64.
6. Sée P, Reimann T, Dumontet C. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer. 2010;67(2):136–143.
7. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–159.
8. Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. *Cancer Lett.* 2013;339(2):159–166.

9. Wang SH, Zhang WJ, Wu XC, et al. Long non-coding RNA Malat1 promotes gallbladder cancer development by acting as a molecular sponge to regulate miR-206. *Oncotarget.* 2016;7(25):37857–37867.

10. Bracconi C, Kogure T, Valer N, et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. *Oncogene.* 2011;30(47):4750–4756.

11. Li S, Huang Y, Huang Y, et al. The long non-coding RNA TP73-AS1 modulates HCC cell proliferation through miR-200a-dependent HMGBl/RAGE regulation. *J Exp Clin Cancer Res.* 2017;36(1):51.

12. Shi X, Ma C, Zhu Q, et al. Upregulation of long intergenic noncoding RNA 00673 promotes tumor proliferation via LSD1 interaction and repression of NCALD in non-small-cell lung cancer. *Oncotarget.* 2016;7(18):25558–25575.

13. Xu J, Zhang R, Zhao J. The Novel Long Noncoding RNA TUSC7 Inhibits Proliferation by Sponging MiR-211 in Colorectal Cancer. *Cell Physiol Biochem.* 2017;41(2):635–644.

14. Salmena L, Poliseno L, Tay K, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? *Cell.* 2011;146(3):353–358.

15. Liu XH, Sun M, Nie FQ, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. *Mol Cancer.* 2014;13:92.

16. Peng W, Si S, Zhang Q, et al. Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression. *J Exp Clin Cancer Res.* 2015;34:79.

17. Burdelski C, Fitzner M, Hube-Magg C, et al. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. *Neoplasia.* 2017;19(4):279–287.

18. Duffy MJ, Mckierman E, O’Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. *Clin Cancer Res.* 2009;15(4):1140–1144.

19. Dong DD, Zhou H, Li G. ADAM15 targets MMP9 activity to promote lung cancer cell invasion. *Oncol Rep.* 2015;34(5):2451–2460.

20. Su X, Wang H, Ge W, et al. An In Vivo Method to Identify microRNA Targets Not Predicted by Computation Algorithms: p21 Targeting by miR-92a in Cancer. *Cancer Res.* 2015;75(14):2875–2885.

21. Zhang G, Jiang G, Wang C, et al. Decreased expression of microRNA-320a promotes proliferation and invasion of non-small cell lung cancer cells by increasing VDAC1 expression. *Oncotarget.* 2016;7(31):49470–49480.

22. Najy AJ, Day KC, Day ML. ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction. *Cancer Res.* 2008;68(4):1092–1099.

23. Yang C, Wu D, Gao L, et al. Competing endogenous RNA networks in human cancer: hypothesis, validation, and perspectives. *Oncotarget.* 2016;7(12):13479–13490.

24. Fatica A, Bozzi I. Long non-coding RNAs: new players in cell differentiation and development. *Nat Rev Genet.* 2015;15(7):7–21.

25. Liu D, Li Y, Luo G, et al. LncRNA SPRY4-T1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. *Cancer Lett.* 2017;388:281–291.

26. Lü MH, Tang B, Zeng S, et al. Long noncoding RNA BC032469, a novel competing endogenous RNA, upregulates hTERT expression by sponging miR-1207-5p and promotes proliferation in gastric cancer. *Oncogene.* 2016;35(27):3524–3534.

27. Wang H, Su X, Yang M, et al. Reciprocal control of miR-197 and IL-6/STAT3 pathway reveals miR-197 as potential therapeutic target for hepatocellular carcinoma. *Oncotarget.* 2015;4(10):e1031490.

28. Sun B, Liu X, Gao Y, Li L, Dong Z. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients. *Br J Biomed Sci.* 2016;73(4):152–157.

29. Li Z, Wang X, Li W, Wu L, Chang L, Chen H. miRNA-124 modulates lung carcinoma cell migration and invasion. *Int J Clin Pharmacol Ther.* 2016;54(8):603–612.

30. Kossmann CM, Annerau M, Thomas-Schoemann A, et al. ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype. *Tumour Biol.* 2017;39(7):10104281771607.

31. Dosch J, Ziemke E, Wan S, et al. Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency. *Oncotarget.* 2017;8(39):65090–65099.

32. Toquet C, Colson A, Jarry A, et al. ADAM15 to e5B1 integrin switch in colon carcinoma cells: a late event in cancer progression associated with tumor dedifferentiation and poor prognosis. *Int J Cancer.* 2012;130(2):278–287.

33. Maretsky T, Le Gall SM, Worpeng-Pietruk S, et al. Src stimulates fibroblast growth factor receptor-2 shedding by an ADAM15 splice variant linked to breast cancer. *Cancer Res.* 2009;69(11):4573–4576.

34. Lucas N, Day ML. The role of the disintegrin metalloproteinase ADAM15 in prostate cancer progression. *J Cell Biochem.* 2009;106(6):967–974.

35. White JM. ADAMs: modulators of cell-cell and cell-matrix interactions. *Curr Opin Cell Biol.* 2003;15(5):598–606.